Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US
Lugano, Switzerland, August 20, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, is pleased to announce that the ready-to-dilute liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US.
This new liquid solution AKYNZEO® injection provides several improvements to storage and handling:
- No refrigeration required at any stage of distribution, preparation, or storage
- Ready-to-dilute solution; no reconstitution required prior to dilution, reducing the preparation process for intravenous administration of AKYNZEO® to one step before use
- May be stored for up to 24 hours at room temperature after dilution, allowing more flexibility in preparation for busy clinicians
- Compatible with intravenous dexamethasone sodium phosphate which can be added to the AKYNZEO® solution or infused simultaneously
AKYNZEO® injection is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy in adults, when given with dexamethasone. It has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO® injection does not contain polysorbate 80 or allergenic excipients such as soy or egg lecithin.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “At Helsinn, we are unwavering in our pursuit to help patients and clinicians in cancer care. These innovations to AKYNZEO® demonstrate our ongoing commitment to the many cancer patients who are at risk of CINV.”
Paul Rittman, CEO, Helsinn Therapeutics (U.S.), Inc, said: “We are very pleased to launch the new IV solution of AKYNZEO, which provides customers with operational advantages for storage, handling, preparation, and administration. We hope that these features will be of assistance to those administering the treatment, allowing for greater efficiency as they help prevent CINV in patients undergoing chemotherapy.”
Clinicians wishing to order the new formulation should contact their GPO or distributor. The National Drug Code (NDC) number for AKYNZEO® injection is 69639-105-01 and the permanent J Code is J1454 (Injection, fosnetupitant 235 mg and palonosetron 0.25 mg; billing unit (single dose vial [SDV]).
AKYNZEO® is the first and only 5-HT3 and NK1 receptor antagonists fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. A single dose of AKYNZEO® given with dexamethasone has been shown to prevent chemotherapy-induced nausea and vomiting for up to 5 days.
AKYNZEO® (netupitant 300mg/palonosetron 0.5mg) capsules was approved in October 2014 in the United States and is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
AKYNZEO® (fosnetupitant 235mg/palonosetron 0.25) for injection was approved in April 2018 and AKYNZEO® injection was approved in May 2020 in the United States. Each is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
Limitations of Use
- AKYNZEO® for injection and AKYNZEO® injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.
AKYNZEO® is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and netupitant or fosnetupitant, substance P/neurokinin-1 (NK-1) receptor antagonists: palonosetron prevents nausea and vomiting mainly during the acute phase and netupitant/fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
About the Helsinn Group
Helsinn is a privately-owned Swiss Pharma Company which, since 1976, has been improving the lives of patients, guided by core family values of respect, integrity and quality. The Group has an extensive portfolio of marketed innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through in-licensing and acquisition to address unmet medical needs. Helsinn operates a unique integrated licensing business model, achieving success with over 80 long-standing partners in 190 countries, who share our values. The Group’s pharmaceutical business, (Helsinn Healthcare) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals, a drug product manufacturer). Helsinn Investment Fund was created to enhance the future of healthcare by providing funding and strategic support to innovative companies.
Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment. Corporate social responsibility is at the heart of everything we do which is reinforced in the company's strategic plan by a commitment to sustainable growth.
To learn more about Helsinn Group please visit www.helsinn.com
- Helsinn Group
- Helsinn Group